

RAS mutants bind inactive RAF

Rothfels, K., Stephens, RM.

European Bioinformatics Institute, New York University Langone Medical Center, Ontario Institute for Cancer Research, Oregon Health and Science University.

The contents of this document may be freely copied and distributed in any media, provided the authors, plus the institutions, are credited, as stated under the terms of <u>Creative Commons Attribution 4.0 International (CC BY 4.0)</u> <u>License</u>. For more information see our <u>license</u>.

18/05/2024

Introduction

Reactome is open-source, open access, manually curated and peer-reviewed pathway database. Pathway annotations are authored by expert biologists, in collaboration with Reactome editorial staff and cross-referenced to many bioinformatics databases. A system of evidence tracking ensures that all assertions are backed up by the primary literature. Reactome is used by clinicians, geneticists, genomics researchers, and molecular biologists to interpret the results of high-throughput experimental studies, by bioinformaticians seeking to develop novel algorithms for mining knowledge from genomic studies, and by systems biologists building predictive models of normal and disease variant pathways.

The development of Reactome is supported by grants from the US National Institutes of Health (P41 HG003751), University of Toronto (CFREF Medicine by Design), European Union (EU STRP, EMI-CD), and the European Molecular Biology Laboratory (EBI Industry program).

Literature references

- Fabregat, A., Sidiropoulos, K., Viteri, G., Forner, O., Marin-Garcia, P., Arnau, V. et al. (2017). Reactome pathway analysis: a high-performance in-memory approach. *BMC bioinformatics, 18*, 142. 7
- Sidiropoulos, K., Viteri, G., Sevilla, C., Jupe, S., Webber, M., Orlic-Milacic, M. et al. (2017). Reactome enhanced pathway visualization. *Bioinformatics*, 33, 3461-3467. A
- Fabregat, A., Jupe, S., Matthews, L., Sidiropoulos, K., Gillespie, M., Garapati, P. et al. (2018). The Reactome Pathway Knowledgebase. *Nucleic Acids Res, 46*, D649-D655. ↗
- Fabregat, A., Korninger, F., Viteri, G., Sidiropoulos, K., Marin-Garcia, P., Ping, P. et al. (2018). Reactome graph database: Efficient access to complex pathway data. *PLoS computational biology*, *14*, e1005968. *オ*

This document contains 1 reaction (see Table of Contents)

RAS mutants bind inactive RAF 7

Stable identifier: R-HSA-6802908

Type: binding

Compartments: plasma membrane

Diseases: cancer



Downstream of oncogenic RAS, a number of pathways are activated in a cancer- and tissue-specific manner. Common effectors include the PI3K/AKT pathway, the RAL GDS pathway and the canonical RAF/MEK/ERK pathway (reviewed in Prior et al, 2012; Pylayeva-Gupta et al, 2011; Stephen et al, 2014). Activation of the RAF/MEK/ERK pathway depends on the recruitment and activation of RAF downstream of oncogenic RAS, although the extent of pathway activation and the importance of the different RAF genes varies among cancer types. For instance, RAF1 (also known as CRAF) is necessary for onset of RAS-driven non-small cell lung cancer and melanoma, but is dispensable in RAS-driven pancreatic ductal adenocarcinoma (Dumaz et al, 2006; Heidorn et al, 2010; Blasco et al, 2011; Karreth et al, 2011; Eser et al, 2013). And although BRAF activity is not required in RAS-driven melanoma as assessed by siRNA knockdown, in the presence of BRAF inhibitors, BRAF paradoxically contributes to pathway activation through dimerization-dependent activation of RAF1 (Dumaz et al, 2006; Heidorn et al, 2010; Poulikakos et al, 2010; Hatzivassiliou et al, 2010; reviewed in Dumaz, 2011; Lito et al, 2013).

Literature references

- Grabocka, E., Pylayeva-Gupta, Y., Bar-Sagi, D. (2011). RAS oncogenes: weaving a tumorigenic web. *Nat. Rev. Cancer, 11*, 761-74. *∧*
- Frese, KK., DeNicola, GM., Baccarini, M., Karreth, FA., Tuveson, DA. (2011). C-Raf is required for the initiation of lung cancer by K-Ras(G12D). *Cancer Discov*, *1*, 128-36. *¬*
- Dumaz, N. (2011). Mechanism of RAF isoform switching induced by oncogenic RAS in melanoma. *Small GTPases, 2*, 289-292. ↗
- Ogilvie, L., Dumaz, N., Martin, J., Bastian, BC., Hedley, D., Hayward, R. et al. (2006). In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. *Cancer Res., 66,* 9483-91. *¬*
- Barbacid, M., Baccarini, M., Santamaría, D., Francoz, S., Cañamero, M., Charron, J. et al. (2011). c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. *Cancer Cell*, *19*, 652-63.

Editions

2015-02-12	Edited	Rothfels, K.
2015-05-18	Authored	Rothfels, K.
2016-08-05	Reviewed	Stephens, RM.